Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBITDA Margin (2018 - 2026)

Sunshine Biopharma filings provide 9 years of EBITDA Margin readings, the most recent being 21.98% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 1092.0% to 21.98% in Q4 2025 year-over-year; TTM through Dec 2025 was 14.35%, a 475.0% increase, with the full-year FY2025 number at 14.35%, up 475.0% from a year prior.
  • EBITDA Margin hit 21.98% in Q4 2025 for Sunshine Biopharma, down from 15.77% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 777.1% in Q4 2021 to a low of 15445.58% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 23.11% (2024), compared with a mean of 1572.81%.
  • Biggest five-year swings in EBITDA Margin: crashed -1458447bps in 2021 and later skyrocketed 1443842bps in 2022.
  • Sunshine Biopharma's EBITDA Margin stood at 777.1% in 2021, then crashed by -176bps to 590.65% in 2022, then skyrocketed by 98bps to 9.88% in 2023, then crashed by -233bps to 32.9% in 2024, then soared by 33bps to 21.98% in 2025.
  • The last three reported values for EBITDA Margin were 21.98% (Q4 2025), 15.77% (Q3 2025), and 7.29% (Q2 2025) per Business Quant data.